Pimenov L T
Probl Endokrinol (Mosk). 1982 Jan-Feb;28(1):26-32.
Altogether 22 patients with diffuse toxic goiter and 14 with neurocirculatory dystonia, treated with lithium carbonate, were examined. Radioimmunoassay of the blood serum triiodothyronine (T3), thyroxine (T4), and thyrotropic hormone (TTH) was used to evaluate the clinical and functional effect of the drug. Lithium carbonate in a dose of 900-1800 mg daily during 4-6 weeks produced a significant reduction in T3 level; the level of T4 was less reduced, and the TTH concentration increased. The pulse rate of patient diminished. Antithyroid effect of the drug is more expressed in patients with medium severity thyrotoxicosis. No side effects were recorded.
对总共22例弥漫性毒性甲状腺肿患者和14例接受碳酸锂治疗的神经循环性肌张力障碍患者进行了检查。采用放射免疫分析法检测血清三碘甲状腺原氨酸（T3）、甲状腺素（T4）和促甲状腺激素（TTH），以评估该药的临床和功能疗效。每天服用900 - 1800毫克碳酸锂，持续4 - 6周，可使T3水平显著降低；T4水平降低幅度较小，TTH浓度升高。患者的脉搏率下降。该药的抗甲状腺作用在中度甲状腺毒症患者中表现更为明显。未记录到副作用。
